Tonix Pharmaceuticals (NASDAQ:TNXP) Raised to Sell at StockNews.com

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Rating) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research note issued on Saturday.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ TNXP opened at $1.67 on Friday. The firm’s 50 day simple moving average is $3.14 and its 200-day simple moving average is $3.91. Tonix Pharmaceuticals has a 12 month low of $1.65 and a 12 month high of $29.94. The stock has a market capitalization of $17.27 million, a price-to-earnings ratio of -0.09 and a beta of 2.17.

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Rating) last announced its quarterly earnings results on Monday, March 13th. The company reported ($3.50) earnings per share for the quarter, beating the consensus estimate of ($5.38) by $1.88. Analysts anticipate that Tonix Pharmaceuticals will post -9.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in shares of Tonix Pharmaceuticals by 490.1% in the first quarter. JPMorgan Chase & Co. now owns 293,036 shares of the company’s stock worth $173,000 after buying an additional 243,380 shares in the last quarter. State Street Corp increased its holdings in shares of Tonix Pharmaceuticals by 309.5% during the 1st quarter. State Street Corp now owns 195,028 shares of the company’s stock worth $115,000 after buying an additional 147,401 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Tonix Pharmaceuticals by 43.5% during the 1st quarter. Geode Capital Management LLC now owns 533,511 shares of the company’s stock valued at $315,000 after buying an additional 161,659 shares during the period. Two Sigma Investments LP lifted its holdings in Tonix Pharmaceuticals by 183.9% in the first quarter. Two Sigma Investments LP now owns 60,191 shares of the company’s stock valued at $36,000 after acquiring an additional 38,991 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Tonix Pharmaceuticals by 1.2% during the 1st quarter. Renaissance Technologies LLC now owns 1,222,424 shares of the company’s stock worth $723,000 after purchasing an additional 14,200 shares during the period. Institutional investors and hedge funds own 9.69% of the company’s stock.

About Tonix Pharmaceuticals

(Get Rating)

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800.